Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.32 |
| ▸ | CHRNG | P07510 | 2/20 | 0.32 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.32 |
| ▸ | CHRND | Q07001 | 2/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | NPY1R | P25929 | 1/20 | 0.30 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.30 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19278961 | 0.82 | — | — | |
| SCHEMBL19278959 | 0.81 | — | — | |
| SCHEMBL17651814 | 0.81 | HSD17B1 (0.38) | — | |
| SCHEMBL17651780 | 0.81 | HSD17B1 (0.38) | — | |
| SCHEMBL19278973 | 0.76 | LCK (0.30) | — | |
| SCHEMBL19278970 | 0.73 | HSP90AA1 (0.36) | HSP90AA1HSP90AB1 | |
| SCHEMBL249200 | 0.73 | HSD17B1 (0.47) | — | |
| SCHEMBL17651802 | 0.73 | PIK3CG (0.30) | — | |
| SCHEMBL19837814 | 0.73 | PIK3CG (0.30) | — | |
| SCHEMBL19278955 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738059-B2 | Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2020-08-11 | — | — | US | disclosed |
| US-20170247384-A1 | CONJUGATES OF PORPHYRINOID PHOTOSENSITIZERS AND GLYCEROL-BASED POLYMERS FOR PHOTODYNAMIC THERAPY | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2017-08-31 | — | — | US | disclosed |
| EP-3210626-A1 | CONJUGATES OF PORPHYRINOID PHOTOSENSITIZERS AND GLYCEROL-BASED POLYMERS FOR PHOTODYNAMIC THERAPY | biolitec Unternehmensbeteiligungs II AG (AT) | 2017-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738059-B2 | Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy | FPGS, PPOX, UROD | HSP90AA1 892/4885HSP90AB1 1428/4885CHRNA1 4876/4885 |
| US-20170247384-A1 | CONJUGATES OF PORPHYRINOID PHOTOSENSITIZERS AND GLYCEROL-BASED POLYMERS FOR PHOTODYNAMIC THERAPY | FPGS, PPOX, UROD | HSP90AA1 892/4885HSP90AB1 1428/4885CHRNA1 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.